Entecavir

證據等級: L5

預測適應症: 10 個

Entecavir: From Hepatitis B Infection to Chronic Hepatitis C Virus Infection

One-Sentence Summary

Entecavir (ETV) is a potent guanosine nucleoside analogue approved globally for chronic hepatitis B virus (HBV) infection, acting as a selective inhibitor of HBV DNA polymerase. The TxGNN model predicts it may be effective for Chronic Hepatitis C Virus Infection with a score of 99.98%; however, of the retrieved evidence — 10 clinical trials and 20 publications — none directly study ETV in HCV treatment, and mechanistic analysis identifies this prediction as a knowledge-graph false positive driven by shared liver-disease nodes between HBV and HCV rather than any real pharmacological basis.

Quick Overview

Item	Content
Original Indication	Chronic Hepatitis B (HBV) infection (globally approved; not registered in Philippines)
Predicted New Indication	Chronic Hepatitis C Virus Infection
TxGNN Prediction Score	99.98%
Evidence Level	L4
Philippines Market Status	✗ Not Marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in this Evidence Pack. Based on established pharmacology, Entecavir is a cyclopentyl guanosine analogue that, after intracellular phosphorylation to its active triphosphate form, inhibits HBV DNA polymerase through three sequential steps: blocking viral DNA priming, reverse transcription of pre-genomic RNA to DNA, and synthesis of positive-strand HBV DNA. This triple inhibition gives ETV one of the highest genetic barriers to resistance among anti-HBV nucleoside analogues (resistance rate <1.2% at five years in treatment-naïve patients), making it a globally recommended first-line therapy for chronic HBV.

The TxGNN model’s association of ETV with HCV most likely arises from knowledge-graph topology rather than pharmacology. HBV and HCV share multiple overlapping disease nodes in the graph — both cause chronic hepatitis, liver cirrhosis, hepatocellular carcinoma, and they frequently co-infect the same patients — creating indirect algorithmic pathways that the model interprets as a drug-disease association and assigns a high confidence score of 99.98%.

In reality, the mechanistic basis for this prediction does not hold. Hepatitis C virus is an RNA virus that replicates exclusively through its NS5B RNA-dependent RNA polymerase (RdRp) — an enzyme that is structurally and functionally unrelated to the HBV DNA polymerase targeted by ETV. No published data demonstrates any anti-HCV activity for ETV at clinically relevant concentrations. More critically, a 2022 cohort study (PMID 36146665) shows that anti-HBV nucleoside analogue therapy — including ETV-containing regimens — can actually trigger HCV reactivation in co-infected patients by removing HCV from viral interference suppression. This is a direct negative signal against the prediction. Furthermore, with modern direct-acting antivirals (DAAs) now curing HCV in over 95% of patients, there is no treatment gap in this indication for ETV to address.

Clinical Trial Evidence

⚠️ Important: None of the retrieved trials directly study Entecavir for HCV treatment. All trials below target HBV infection or use ETV as a background/comparator agent. They are presented as retrieved evidence but do not support repurposing Entecavir for chronic HCV.

Trial Number	Phase	Status	Enrollment	Key Findings
NCT02555943	Phase 2/3	Completed	23	Prospective study of DAA therapy for HCV in HBV/HCV co-infected patients; monitors HBV reactivation during HCV treatment. ETV used to manage HBV, not as the HCV treatment
NCT04405011	N/A	Unknown	60	3-arm RCT evaluating whether prophylactic nucleoside analogues (NUC) can prevent HBV reactivation in HCV/HBV co-infected patients receiving DAA therapy for chronic HCV; ETV role is HBV prophylaxis only
NCT01018381	N/A	Completed	130	Randomized study of Arabinoxylan rice bran (MGN-3/Biobran) for HCC and hepatitis B and C infection; ETV is not the primary investigational agent
NCT06566248	Phase 2	Recruiting	90	Double-blind RCT evaluating TQA3810 tablets combined or uncombined with nucleoside analogues in HBV patients; indication is HBV, not HCV
NCT01270178	N/A	Unknown	420	Prospective ETV trial in HBV-related HCC patients after radiofrequency ablation; not an HCV study
NCT00597259	Phase 4	Unknown	294	Pegasys+ETV vs ETV alone in HBeAg-positive chronic HBV; references HCV/HIV treatment concepts as background rationale but exclusively targets HBV
NCT03662568	Phase 1	Completed	56	Drug-drug interaction study of Morphothiadine Mesilate/Ritonavir combined with ETV or TDF in healthy subjects; pharmacokinetics only, not a therapeutic efficacy trial
NCT05484466	Phase 2	Unknown	90	ZM-H1505R+ETV vs ETV monotherapy in CHB patients on long-term ETV; exclusively an HBV study
NCT00096785	Phase 3	Completed	69	Phase 3 RCT comparing ETV vs adefovir for early viral-load reduction in nucleoside-naïve HBV adults; not an HCV trial
NCT05423106	Phase 1	Terminated	60	First-in-human study of JNJ-64457744 in healthy volunteers and HBV patients; terminated early; not an ETV–HCV efficacy trial

Literature Evidence

PMID	Year	Type	Journal	Key Findings
36146665	2022	Cohort	Viruses	Negative signal: HCV reactivation observed in anti-HCV antibody-positive CHB patients after nucleoside analogue therapy (including ETV); ETV treatment of HBV may paradoxically promote, not suppress, HCV replication
25027705	2014	Review	Minerva Gastroenterologica	Comparative review of antivirals for HBV and HCV and their renal effects; ETV discussed exclusively as an HBV agent with no anti-HCV activity mentioned
24773464	2014	Review	Expert Opinion on Pharmacotherapy	HBV/HCV coinfection treatment; ETV manages the HBV component while DAAs address HCV — mechanisms are entirely separate
22959099	2013	Review	Clinics in Research in Hepatology	HBV/HCV dual infection as a therapeutic challenge; ETV used for the HBV component of co-infection, separate agents required for HCV
28538267	2017	Cohort	European Journal of Gastroenterology & Hepatology	Cirrhosis does not impair ETV efficacy in CHB; uses HCV cohort data for contextual comparison only — no ETV-HCV treatment data
16937041	2006	Review	Wiener Medizinische Wochenschrift	Historical review of HBV and HCV treatment options; ETV presented only as an HBV agent
32173307	2020	Review	Clinics in Research in Hepatology	Pediatric management of viral hepatitis B and C; ETV approved for HBV in children, entirely separate agents used for HCV
24868325	2014	Review	World Journal of Hepatology	HBV and HCV management before and after liver/kidney transplantation; ETV used for HBV prophylaxis, distinct treatment pathway for HCV
28487602	2017	Review	World Journal of Gastroenterology	HBV and alcoholic liver disease expected to become leading HCC causes in the post-DAA era; ETV discussed for HBV only
39351520	2024	Review	World Journal of Hepatology	Metabolomics as an emerging diagnostic tool in liver disease; ETV referenced in HBV context with no pharmacological connection to HCV

Philippines Market Information

Entecavir currently has no registered products with the Philippines FDA. The drug is not marketed in the Philippines and carries no local authorization numbers. Any clinical use in the Philippines would require a full regulatory submission to the Philippines FDA (Food and Drug Administration).

For reference, the drug is commercially available internationally under brand names including Baraclude® (Bristol-Myers Squibb) and numerous generic formulations, all approved for chronic hepatitis B treatment.

Safety Considerations

Please refer to the package insert for safety information.

Critical co-infection warning (from the Evidence Pack mechanistic analysis): Entecavir must not be used as the sole antiviral agent in HIV/HBV co-infected patients who are not on fully suppressive antiretroviral therapy. ETV monotherapy in HIV-positive individuals can select for the M184V/I resistance mutation in HIV reverse transcriptase, permanently compromising the efficacy of lamivudine and emtricitabine in future antiretroviral regimens. Patients with HIV/HBV co-infection must receive a complete antiretroviral regimen before ETV is considered.

Conclusion and Next Steps

Decision: Hold

Rationale: This TxGNN prediction is a knowledge-graph false positive. Entecavir targets HBV DNA polymerase and has no pharmacological mechanism to inhibit HCV NS5B RNA-dependent RNA polymerase. Published cohort data (PMID 36146665) demonstrate the opposite effect — ETV-based HBV suppression can promote HCV reactivation in co-infected patients. With DAA regimens already curing HCV in over 95% of cases, there is no clinical or scientific basis to pursue ETV for this indication.

Contextual observations from the full TxGNN prediction ranking:

Rank	Indication	Evidence Level	Recommendation	Note
2	Hepatitis B virus infection	L1	Proceed with Guardrails	ETV’s globally approved indication; the Philippines non-registration is an access gap, not a repurposing question
3	HIV infectious disease	L3	Hold	ETV has demonstrated partial HIV-1 reverse transcriptase inhibition in small clinical studies (PMID 17582071; PMID 18453854), but cannot be used as standalone HIV therapy due to M184V resistance risk

To proceed with the HBV Philippines market access opportunity, the following is needed:

Prepare and submit a Philippines FDA registration dossier for Entecavir (tablet formulation)
Obtain official package insert with translations; ensure HIV co-infection warning and CKD dose-adjustment guidance are clearly communicated
Engage local hepatology and infectious disease societies to align treatment guidelines with WHO and regional HBV prevalence data
Establish pharmacovigilance protocols for long-term HBV suppression, with particular attention to renal function monitoring
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.